Global Human Papillomavirus (HPV) Vaccines Market - 2024-2031

Global Human Papillomavirus (HPV) Vaccines Market - 2024-2031

The global human papillomavirus (HPV) vaccine market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.

Human papillomavirus (HPV) is a viral infection that affects the skin, body orifices, and mucus membranes. It is one of the common sexually transmitted infections (STI) transmitted through skin-to-skin contact. The purpose of the human papillomavirus (HPV) vaccination is to guard against infection by specific HPV strains that can result in genital warts and several malignancies, including oropharyngeal, cervical, and anal cancers.

The vaccination lowers the risk of infection upon exposure by inducing the immune system to develop antibodies against the virus. According to CDC, vaccination against HPV can be started at the age of 9, but recommended at 11-12 years. Vaccination is a crucial component of public health initiatives aimed at preventing HPV-related illnesses, since it has demonstrated a substantial reduction in the occurrence of these problems.

Market Dynamics: Drivers

Rising vaccination drives against HPV

Rising vaccination drives against HPV are expected to drive market growth. As the prevalence of HPV is on the rise, the majority of government organizations are taking initiatives to increase the vaccine reach to tackle HPV infection. Strategic initiatives by health agencies such as WHO, CDC, UNICEF, and others to raise the supply of vaccines to all countries and to implement vaccination drives are expected to boost the overall market growth.

For instance, according to a UNICEF report, the organization sought to obtain 36 million doses of HPV vaccine, with 52 countries and 7 new entries among the targets. UNICEF added that the arrival of new suppliers will change the HPV vaccine market by 2024.

Also, According to WHO, in October 2023 Nigeria started a vaccine campaign against the human papillomavirus, which is the cause of cervical cancer. The goal of the immunization campaign was to vaccinate 7.7 million females at once. Additionally, Nigeria will continue to include HPV in its regular vaccination drives.

On April 27, 2023, As per a news release issued by GAVI, the partners in the vaccination alliance set a goal to provide vaccines to every country and around 86 million girls who are susceptible to cervical cancer by 2025.

Moreover, the rising prevalence of cervical cancer, and recent product approvals by WHO are expected to further propel the market growth.

Restraints

Factors such as the high cost of the vaccine, lack of awareness regarding the importance of vaccination, and limited availability of the vaccine are expected to restrain the market growth.

For instance, according to a Sabin Vaccine Institute, many women and young girls in low- and middle-income countries do not have access to the HPV vaccine and are unaware of its value. Even though the HPV vaccine has been available for the past 17 years, just 21% of eligible girls worldwide have received it.

Segment Analysis

The global HPV vaccine market is segmented based on type, gender, age group, end users and region.

The quadrivalent segment in type accounted for approximately 37.5% of the human papillomavirus (HPV) vaccine market share

Currently, the vaccine market for HPV is dominated by the two major brands marketed by Merck & Co. and GSK Plc. Merck & Co. received FDA approval for its HPV vaccine brand Gardasil in 2006 and has been marketing it since then all across the world. Whereas GSK has received the market authorization in several regions in the early 20’s. Merck manufactures two brands “Gardasil” a quadrivalent vaccine and “Gardasil 9” a nonavalent vaccine both are recombinant types. These vaccines have been dominating the market with the highest revenue as compared to the GSK brands. This is due to price variation and differences in annual production volume. Moreover, the monopoly of Merck’s brand in the U.S., a high-income country and also where the HPV vaccination is of greater priority has been one of the major factors for higher market share.

For instance, according to Merck's latest annual report, sales for the Gardasil brand were $5.6 billion in 2021, $6.8 billion in 2022, and $8.8 billion in 2023. However, according to the latest annual report released by GSK, Cervarix's brand only brought in $132 million revenue in 2023.

Geographical Analysis

North America is expected to dominate the market with 42.4% share in the Global HPV Market

North America is expected to dominate the market due to the increasing prevalence of HPV-related diseases, particularly cervical cancer and genital warts. The United States dominates the market because it has the highest immunization rate in the world as compared to other countries.

For instance, on February 24, 2024, according to data released by the Centers for Disease Control and Prevention, 38.6% of children aged 9 to 17 had received one or more doses of the HPV vaccine in 2022. This is greater than the 21% global coverage of the first HPV dose for the same year.

Moreover, the American Cancer Society has set a goal to eradicate vaccine-preventable HPV cancers by promoting vaccine drives in the United States. The society aims to reach a vaccination rate of 80% for the 13-year-old population by 2026. This strategic initiative is expected to boost the North America market.

Moreover, the region's dominance in the market is attributed to favorable reimbursement conditions and the introduction of HPV vaccination programs at community health centers and schools.

COVID-19 Impact Analysis

The global market for the human papillomavirus (HPV) vaccination has been significantly impacted by the COVID-19 epidemic. The supply chain for routine vaccines including HPV has been significantly impacted by the pandemic. The vaccine reach for HPV infection has decreased as a result of the increased significance of the emergency COVID-19 immunization. Moreover, the community immunization campaigns were restricted because of rules in schools and community centers where routine immunization against HPV majorly takes place.

For instance, on October 12, 2022, according to an article published by the Center for Strategic & International Studies. Stated that there has been a pause in HPV vaccination, and the global coverage was reduced by 15% as compared to pre-pandemic years. Also, the article stated that HPV vaccination was one of the first programs to get halted during the pandemic due to the diversion of healthcare workers toward COVID-19 rescue efforts.

Market Segmentation

By Type
• Bivalent
• Quadrivalent
• Nona valent

By Gender
• Female
• Male

By Age Group
• Children
• Adults
• Geriatrics

By End Users
• Hospitals
• Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the human papillomavirus (HPV) vaccine market include Merck & Co., Inc., GSK plc., Wantai BioPharm., Walvax Biotechnology Co., Ltd., and Serum Institute of India Pvt. Ltd. among others.

Key developments

 On January 24, 2023, On the occasion of National Girl Child Day, Serum Institute of India Pvt. Ltd. introduced CERVAVAC, the first HPV vaccine in India. The Bill and Melinda Gates Foundation, the Biotechnology Industry Research Assistance Council (BIRAC), and the Department of Biotechnology (DBT) collaborated to produce the vaccine. The goal of SII is to provide access to the vaccine for Indian women who may be at risk of acquiring cervical cancer.

 On April 14, 2023, Walvax Biotechnology Co., Ltd. released the safety and preliminary immunogenicity data from the Phase 1 clinical trial of Walrinvax. According to the study, this novel vaccine is well tolerated at both high and low doses.

Why Purchase the Report?
• To visualize the global HPV vaccine market segmentation based on type, gender, age group, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of HPV vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global HPV vaccine market report would provide approximately 55 tables, 56 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies